Lipertance (Amlodipine Besilate, Perindopril Arginine, Atorvastatin Calcium Trihydrate)

Lipertance acts on cardiovascular pathways to control blood pressure and lipid levels.

• Hypertension: lowers systolic and diastolic pressure through vasodilation and renin‑angiotensin blockade.
• Hyperlipidemia: reduces LDL‑cholesterol and triglycerides by inhibiting cholesterol synthesis.
• Prevention of cardiovascular events: decreases the risk of myocardial infarction, stroke and related complications in high‑risk patients.

• Amlodipine besilate blocks L‑type calcium channels in vascular smooth muscle, causing vasodilation. Perindopril arginine inhibits angiotensin‑converting enzyme, reducing angiotensin II formation and further promoting vasodilation while decreasing aldosterone secretion. Atorvastatin calcium trihydrate inhibits HMG‑CoA reductase, the rate‑limiting enzyme in hepatic cholesterol synthesis, leading to lower circulating LDL‑cholesterol and overall lipid improvement.

Lipertance may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate pain often occurring early in therapy.
• Dizziness or light‑headedness: related to blood‑pressure lowering.
• Peripheral edema: swelling of ankles or lower legs.
• Cough: dry throat irritation from ACE inhibition.
• Muscle pain or weakness: associated with statin component.
• Gastrointestinal upset: nausea, abdominal discomfort or dyspepsia.

Serious or Rare Side Effects

• Angioedema: rapid swelling of face, lips, tongue or airway.
• Severe liver injury: jaundice, elevated transaminases, hepatic failure.
• Rhabdomyolysis: muscle breakdown with dark urine and renal risk.
• Marked hypotension: symptomatic low blood pressure.
• Myocardial infarction: rare paradoxical cardiac events.
• Pancreatitis: abdominal pain with elevated enzymes.

Before initiating Lipertance, several safety considerations should be reviewed.

• Blood pressure monitoring: check regularly during initiation and dose adjustments.
• Liver function assessment: evaluate baseline enzymes and monitor periodically due to the statin component.
• Renal function evaluation: assess kidney status, especially in patients on perindopril.
• Pregnancy and lactation: avoid unless clearly indicated and benefits outweigh risks.
• Drug interaction review: identify concomitant medicines that may alter efficacy or safety.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Lipertance can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

• Potassium‑sparing diuretics: increase risk of hyperkalaemia.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): raise atorvastatin exposure and muscle toxicity.
• ACE inhibitor combined with ARB or direct renin inhibitor: additive renal impairment.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive effect and affect renal function.
• Other CYP3A4‑metabolised statins: monitor for myopathy.
• Beta‑blockers: enhanced blood‑pressure lowering may require dose adjustment.